Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
de Boniface J, Filtenborg Tvedskov T, Rydén L, Szulkin R, Reimer T, Kühn T, Kontos M, Gentilini OD, Olofsson Bagge R, Sund M, Lundstedt D, Appelgren M, Ahlgren J, Norenstedt S, Celebioglu F, Sackey H, Scheel Andersen I, Hoyer U, Nyman PF, Vikhe Patil E, Wieslander E, Dahl Nissen H, Alkner S, Andersson Y, Offersen BV, Bergkvist L, Frisell J, Christiansen P; SENOMAC Trialists’ Group; SENOMAC Trialists' Group. de Boniface J, et al. Among authors: frisell j. N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487. N Engl J Med. 2024. PMID: 38598571 Clinical Trial.
Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Rydén L, Olofsson Bagge R, Sund M, Johansson H, Lundstedt D; SENOMAC Trialists’ Group. de Boniface J, et al. Among authors: frisell j. BMC Cancer. 2017 May 26;17(1):379. doi: 10.1186/s12885-017-3361-y. BMC Cancer. 2017. PMID: 28549453 Free PMC article. Clinical Trial.
Do clinical trials truly mirror their target population? An external validity analysis of national register versus trial data from the Swedish prospective SENOMIC trial on sentinel node micrometastases in breast cancer.
Andersson Y, Bergkvist L, Frisell J, de Boniface J. Andersson Y, et al. Among authors: frisell j. Breast Cancer Res Treat. 2019 Sep;177(2):469-475. doi: 10.1007/s10549-019-05328-3. Epub 2019 Jun 24. Breast Cancer Res Treat. 2019. PMID: 31236811 Free PMC article.
The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer.
de Boniface J, Ahlgren J, Andersson Y, Bergkvist L, Frisell J, Lundstedt D, Olofsson Bagge R, Rydén L, Sund M; SENOMAC Trialists’ Group. de Boniface J, et al. Among authors: frisell j. Breast Cancer Res Treat. 2020 Feb;180(1):167-176. doi: 10.1007/s10549-020-05537-1. Epub 2020 Jan 27. Breast Cancer Res Treat. 2020. PMID: 31989379 Free PMC article.
Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial.
Appelgren M, Sackey H, Wengström Y, Johansson K, Ahlgren J, Andersson Y, Bergkvist L, Frisell J, Lundstedt D, Rydén L, Sund M, Alkner S, Vrou Offersen B, Filtenborg Tvedskov T, Christiansen P, de Boniface J; SENOMAC Trialists' Group. Appelgren M, et al. Among authors: frisell j. Breast. 2022 Jun;63:16-23. doi: 10.1016/j.breast.2022.02.013. Epub 2022 Mar 1. Breast. 2022. PMID: 35279508 Free PMC article.
False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy.
de Boniface J, Frisell J, Kühn T, Wiklander-Bråkenhielm I, Dembrower K, Nyman P, Zouzos A, Gerber B, Reimer T, Hartmann S. de Boniface J, et al. Among authors: frisell j. Breast Cancer Res Treat. 2022 Jun;193(3):589-595. doi: 10.1007/s10549-022-06588-2. Epub 2022 Apr 22. Breast Cancer Res Treat. 2022. PMID: 35451733 Free PMC article.
114 results